The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD.

When considering the MAP (low vs high) and treatment choice (ruxolitinib vs no ruxolitinib), patients with low MAP who received ruxolitinib had higher D28 ORR compared with those receiving nonruxolitinib therapies (65% vs 39%, P = .027); a similar difference was observed in patients with high MAP although this did not reach statistical significance (ruxolitinib: 43%, no ruxolitinib: 23%, P = .08) ( Figure 1 C).

also in 111,027 other papers